BB's improving financial performance, strategic initiatives/collaborations and focus on IoT and Secure Communications units position it for long-term growth.

Tower Semiconductor Ltd. (NASDAQ:TSEM ) Q4 2024 Earnings Conference Call February 10, 2024 10:00 AM ET Company Participants Noit Levi - Senior Vice President of Investor Relations and Corporate Communications Russell Ellwanger - Chief Executive Officer Oren Shirazi - Chief Financial Officer, Senior Vice President of Finance Conference Call Participants Cody Acree - Benchmark Bastien Faucon-Morin - SIG Richard Shannon - Craig Hallum Lisa Thompson - ZACKS Investment Research Matthew Bryson - Wedbush Operator Good day and thank you for standing by.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended December 31, 2024.

Q4 Highlights: Revenue of $252.4 million Operating Margin of 21.6% Diluted earnings per share of $1.54 BEVERLY, Mass. , Feb. 10, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced financial results for the fourth quarter and full year ended December 31, 2024.

CHICAGO , Feb. 10, 2025 /PRNewswire/ -- Heidrick & Struggles International, Inc. (Nasdaq: HSII) ("Heidrick & Struggles", "Heidrick" or the "Company"), a premier provider of global leadership advisory and on-demand talent solutions, today announced it will host its quarterly conference call to discuss fourth quarter and full year 2024 financial results on Monday, March 3, 2025, at 5:00pm ET. The conference call and accompanying slides will be publicly available via live webcast on the investor relations section of the Heidrick & Struggles website at www.heidrick.com.

SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock. In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount …

SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), The Infrastructure Cloud™ company, today announced it will release financial results for the fourth quarter of its 2025 fiscal year, which ended January 31, 2025, after the U.S. markets close Thursday, March 6, 2025.

~Ends 2024 With Triple Digit Growth Across All Electrification Metrics~ MARLBOROUGH, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- ConnectM Technology Solutions, Inc. (NASDAQ:CNTM) ("ConnectM" or the "Company"), a technology company focused on the electrification economy, today published its impact scorecard for the fourth quarter of 2024.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128496&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) and certain of its officers.

CRANBURY, N.J. , Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ModivCare, Inc. (“ModivCare” or “the Company”) (NASDAQ: MODV) and certain of its officers.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. So what: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MGP Ingredients, Inc. (“MGP Ingredients” or “the Company”) (NASDAQ: MGPI) and certain of its officers.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integral Ad Science Holding Corp. (“IAS” or “the Company”) (NASDAQ: IAS) and certain of its officers.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Grocery Outlet Holding Corp. (“Grocery Outlet” or “the Company”) (NASDAQ: GO) and certain of its officers.

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ: EPIX) and certain of its officers.

Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported certain preliminary unaudited financial results for the full year ended December 31, 2024, including cash, cash equivalents, and revenues, and also provided a business update.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=128486&wire=1 or contact Joseph E. Levi, Esq.